Compounds > oxybutynin
Page last updated: 2024-11-02

oxybutynin and Abdominal Migraine

oxybutynin has been researched along with Abdominal Migraine in 12 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Research Excerpts

ExcerptRelevanceReference
" Systemic adverse events were consistent with previous triptan trials, and included dizziness, paresthesia, muscle tightness, and nausea, all of which occurred in < 5% of patients in any group."2.87Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine. ( Brandes, JL; Kellerman, DJ; Kudrow, DB; Schmidt, PC; Spierings, EL; Tepper, SJ; Weintraub, J, 2018)
" Migraine-associated gastroparesis can impair absorption and reduce bioavailability of oral migraine medications and thereby reduce and delay therapeutic efficacy."2.77Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. ( Goldstein, J; Pierce, MW; Pugach, N; Silberstein, S; Singer, R; Smith, TR, 2012)
"One third of patients who experience migraine-related nausea report that this symptom interferes with their ability to take oral medications."2.77A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. ( Goldstein, J; Griesser, J; Pierce, M; Pugach, N; Sebree, T; Smith, TR, 2012)
"Many migraineurs awake early in the morning with their attack progressing and already associated with nausea and vomiting."2.46Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. ( Freitag, F; Pearlman, SH; Rapoport, AM, 2010)
" Pharmacokinetic studies showed that the ADAM 1."1.48Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray. ( Ameri, M; Diep, AN; Hochart, G; Lewis, H; Nguyen, J; Queja, A, 2018)
" As of 2018, the FDA Adverse Event Reporting System public dashboard lists a total of 2889 reports of safety problems with the patch, 904 of which were classified as serious."1.48Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. ( Burch, RC; Loder, EW; Rayhill, M, 2018)
"Because migraine attacks can be disabling, with many patients unable to perform their usual activities, it is important for prescribers and their patients to be confident that they will be able to assemble and apply sumatriptan TDS in the middle of an attack."1.40Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks. ( Foster, S; Jennings, C; Meadows, KP; O'Neill, C; Pierce, M, 2014)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Spierings, EL1
Brandes, JL1
Kudrow, DB1
Weintraub, J1
Schmidt, PC1
Kellerman, DJ1
Tepper, SJ1
Nguyen, J1
Lewis, H1
Queja, A1
Diep, AN1
Hochart, G1
Ameri, M1
Loder, EW1
Rayhill, M1
Burch, RC1
Meadows, KP1
Pierce, M2
O'Neill, C1
Foster, S1
Jennings, C1
Tepper, DE1
Aschenbrenner, DS1
Rapoport, AM1
Freitag, F1
Pearlman, SH1
Tfelt-Hansen, P1
Almén-Christensson, A1
Hammar, M1
Lindh-Åstrand, L1
Landtblom, AM1
Brynhildsen, J1
Smith, TR2
Goldstein, J2
Singer, R1
Pugach, N2
Silberstein, S1
Pierce, MW1
Griesser, J1
Sebree, T1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine[NCT02745392]Phase 2/Phase 3365 participants (Actual)Interventional2016-06-30Completed
[NCT00204074]Phase 2/Phase 30 participants Interventional2001-10-31Active, not recruiting
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months[NCT00792103]Phase 3198 participants (Actual)Interventional2009-01-31Completed
The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study[NCT00724815]Phase 3530 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)

The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success. (NCT02745392)
Timeframe: 2 hours

InterventionParticipants (Count of Participants)
Placebo33
ZP-Zolmitriptan 1 mg45
ZP-Zolmitriptan 1.9 mg44
ZP-Zolmitriptan 3.8 mg56

Proportion of Subjects With Pain Freedom

Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours. (NCT02745392)
Timeframe: 2 hours

InterventionParticipants (Count of Participants)
Placebo11
ZP-Zolmitriptan 1 mg24
ZP-Zolmitriptan 1.9 mg23
ZP-Zolmitriptan 3.8 mg34

Nausea Free

Nausea free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101143

Pain Relief

Headache pain relief (no pain or mild headache pain) at two hours post activation of NP101. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101105

Phonophobia Free

Phonophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipants (Number)
NP101109

Photophobia Free

Photophobia free at two hours after patch activation. (NCT00792103)
Timeframe: 2 hours

Interventionparticipant (Number)
NP10197

Subject Self-examination of Skin Irritation

For each patch application, subjects performed a self-examination of skin irritation using a 5-point scale (0=no redness; 1=minimal skin redness; 2=moderate skin redness with sharp borders; 3=intense skin redness with or without swelling; 4=intense skin redness with blisters or broken skin). (NCT00792103)
Timeframe: 24 hours post patch activation

Interventionscores on a scale (Mean)
NP1011.0

Nausea Free at Two Hours

Number of subjects who were nausea free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation

Interventionparticipants (Number)
NP101 Patch189
Placebo Patch144

Pain Free at Two Hours

Subjects whose headache severity score equaled zero (0) two hours post patch activation and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation

Interventionparticipants (Number)
NP101 Patch40
Placebo Patch21

Phonophobia Free at Two Hours

Subjects who were phonophobia free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation

Interventionparticipants (Number)
NP101 Patch125
Placebo Patch89

Photophobia Free at Two Hours

Subjects who were photophobia free and who had not received any rescue medication before their two-hour assessment. (NCT00724815)
Timeframe: 2 hours post patch activation

Interventionparticipants (Number)
NP101 Patch116
Placebo Patch83

Reviews

2 reviews available for oxybutynin and Abdominal Migraine

ArticleYear
Sumatriptan iontophoretic patch for migraine.
    Headache, 2014, Volume: 54, Issue:9

    Topics: Humans; Iontophoresis; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Transderm

2014
Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine.
    CNS drugs, 2010, Volume: 24, Issue:11

    Topics: Clinical Trials as Topic; Drug Administration Routes; Female; Gastroparesis; Humans; Iontophoresis;

2010

Trials

4 trials available for oxybutynin and Abdominal Migraine

ArticleYear
Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
    Cephalalgia : an international journal of headache, 2018, Volume: 38, Issue:2

    Topics: Administration, Cutaneous; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine D

2018
Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study.
    Fertility and sterility, 2011, Volume: 96, Issue:2

    Topics: Administration, Cutaneous; Adult; Cross-Over Studies; Double-Blind Method; Drug Administration Sched

2011
Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
    Headache, 2012, Volume: 52, Issue:4

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chemistry, Pharmaceutical; Female; Follow-Up Stu

2012
A sumatriptan iontophoretic transdermal system for the acute treatment of migraine.
    Headache, 2012, Volume: 52, Issue:9

    Topics: Adult; Analgesics; Double-Blind Method; Female; Humans; Iontophoresis; Male; Migraine Disorders; Sum

2012

Other Studies

6 other studies available for oxybutynin and Abdominal Migraine

ArticleYear
Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray.
    Journal of pharmaceutical sciences, 2018, Volume: 107, Issue:8

    Topics: Administration, Cutaneous; Animals; Biological Availability; Drug Delivery Systems; Equipment Design

2018
Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process.
    Headache, 2018, Volume: 58, Issue:10

    Topics: Adverse Drug Reaction Reporting Systems; Burns, Chemical; Cicatrix; Clinical Trials as Topic; Drug A

2018
Sumatriptan transdermal system can be correctly assembled and applied during migraine attacks.
    Headache, 2014, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Iontophoresis; Male; Mi

2014
A sumatriptan patch (Zecuity) for migraine.
    The Medical letter on drugs and therapeutics, 2015, Nov-09, Volume: 57, Issue:1481

    Topics: Adult; Double-Blind Method; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Serot

2015
Sumatriptan Patch is Temporarily Suspended.
    The American journal of nursing, 2016, Volume: 116, Issue:9

    Topics: Administration, Cutaneous; Burns; Drug-Related Side Effects and Adverse Reactions; Humans; Migraine

2016
Low efficacy of transdermal sumatriptan in migraine.
    CNS drugs, 2011, Volume: 25, Issue:2

    Topics: Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Sumatriptan; Transdermal Patch; T

2011